Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1703
    +0.0009 (+0.08%)
     
  • GBP/USD

    1.2624
    +0.0002 (+0.01%)
     
  • Bitcoin GBP

    56,025.91
    +718.72 (+1.30%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,369.18
    +201.11 (+0.50%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

Shire misses Q2 earnings forecast, raises outlook

LONDON, July 23 (Reuters) - Shire (Xetra: S7E.DE - news) , the London-listed maker of drugs to treat hyperactivity and rare diseases, missed market expectations for second-quarter earnings after lower sales of its ADHD drug Intuniv following the introduction of generic competition.

The company reported non-GAAP earnings per share of $2.63 on Thursday, a rise at constant exchange rates, but short of analysts' forecasts of $2.80, on revenue up 9 percent to $1.56 billion.

However, it said it now expected its earnings growth for the year to be in the mid-to-high single digit range, up from its forecast of mid single digits made in April. (Reporting by Paul Sandle; Editing by Neil Maidment)